These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

264 related articles for article (PubMed ID: 28347636)

  • 1. Knowledge of hepatitis C and treatment willingness amongst people who inject drugs in an era of direct acting antivirals.
    Mah A; Hull MW; DeBeck K; Milloy MJ; Dobrer S; Nosova E; Wood E; Kerr T; Hayashi K
    Int J Drug Policy; 2017 Sep; 47():137-143. PubMed ID: 28347636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatitis C care continuum and associated barriers among people who inject drugs in Chennai, India.
    Patel EU; Solomon SS; Mcfall AM; Srikrishnan AK; Pradeep A; Nandagopal P; Laeyendecker O; Tobian AAR; Thomas DL; Sulkowski MS; Kumar MS; Mehta SH
    Int J Drug Policy; 2018 Jul; 57():51-60. PubMed ID: 29679811
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-term injection drug use changes following hepatitis C virus (HCV) assessment and treatment among persons who inject drugs with acute HCV infection.
    Artenie AA; Zang G; Daniel M; Fortier E; Jutras-Aswad D; Puzhko S; Bruneau J
    Int J Drug Policy; 2017 Sep; 47():239-243. PubMed ID: 28587944
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 'Hep C's like the common cold': understanding barriers along the HCV care continuum among young people who inject drugs.
    Skeer MR; Ladin K; Wilkins LE; Landy DM; Stopka TJ
    Drug Alcohol Depend; 2018 Sep; 190():246-254. PubMed ID: 30071457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Eligibility of persons who inject drugs for treatment of hepatitis C virus infection.
    Arain A; Robaeys G
    World J Gastroenterol; 2014 Sep; 20(36):12722-33. PubMed ID: 25278674
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Injecting risk behaviours following treatment for hepatitis C virus infection among people who inject drugs: The Australian Trial in Acute Hepatitis C.
    Alavi M; Spelman T; Matthews GV; Haber PS; Day C; van Beek I; Walsh N; Yeung B; Bruneau J; Petoumenos K; Dolan K; Kaldor JM; Dore GJ; Hellard M; Grebely J;
    Int J Drug Policy; 2015 Oct; 26(10):976-83. PubMed ID: 26115881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus control among persons who inject drugs requires overcoming barriers to care.
    Zeremski M; Zibbell JE; Martinez AD; Kritz S; Smith BD; Talal AH
    World J Gastroenterol; 2013 Nov; 19(44):7846-51. PubMed ID: 24307778
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatitis C virus reinfection after successful treatment with direct-acting antiviral therapy in a large population-based cohort.
    Rossi C; Butt ZA; Wong S; Buxton JA; Islam N; Yu A; Darvishian M; Gilbert M; Wong J; Chapinal N; Binka M; Alvarez M; Tyndall MW; Krajden M; Janjua NZ;
    J Hepatol; 2018 Nov; 69(5):1007-1014. PubMed ID: 30142429
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disparities in uptake of direct-acting antiviral therapy for hepatitis C among people who inject drugs in a Canadian setting.
    Socías ME; Ti L; Wood E; Nosova E; Hull M; Hayashi K; Debeck K; Milloy MJ
    Liver Int; 2019 Aug; 39(8):1400-1407. PubMed ID: 30653809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determinants of hepatitis C antiviral effectiveness awareness among people who inject drugs in the direct-acting antiviral era.
    Valerio H; McAuley A; Innes H; Palmateer N; Goldberg DJ; Munro A; Taylor A; Hutchinson SJ
    Int J Drug Policy; 2018 Feb; 52():115-122. PubMed ID: 29414462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estimating the cascade of hepatitis C testing, care and treatment among people who inject drugs in Australia.
    Iversen J; Grebely J; Catlett B; Cunningham P; Dore GJ; Maher L
    Int J Drug Policy; 2017 Sep; 47():77-85. PubMed ID: 28578863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis C virus testing, liver disease assessment and treatment uptake among people who inject drugs pre- and post-universal access to direct-acting antiviral treatment in Australia: The LiveRLife study.
    Bajis S; Grebely J; Hajarizadeh B; Applegate T; Marshall AD; Ellen Harrod M; Byrne J; Bath N; Read P; Edwards M; Gorton C; Hayllar J; Cock V; Peterson S; Thomson C; Weltman M; Jefferies M; Wood W; Haber P; Ezard N; Martinello M; Maher L; Dore GJ;
    J Viral Hepat; 2020 Mar; 27(3):281-293. PubMed ID: 31698545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis C treatment uptake among people who inject drugs in the oral direct-acting antiviral era.
    Falade-Nwulia O; Gicquelais RE; Astemborski J; McCormick SD; Kirk G; Sulkowski M; Thomas DL; Mehta SH
    Liver Int; 2020 Oct; 40(10):2407-2416. PubMed ID: 32770638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis C cascade of care among people who inject drugs in Vancouver, Canada.
    Young S; Wood E; Milloy MJ; DeBeck K; Dobrer S; Nosova E; Kerr T; Hayashi PhD K
    Subst Abus; 2018; 39(4):461-468. PubMed ID: 29949450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver disease knowledge and acceptability of non-invasive liver fibrosis assessment among people who inject drugs in the drug and alcohol setting: The LiveRLife Study.
    Marshall AD; Micallef M; Erratt A; Telenta J; Treloar C; Everingham H; Jones SC; Bath N; How-Chow D; Byrne J; Harvey P; Dunlop A; Jauncey M; Read P; Collie T; Dore GJ; Grebely J
    Int J Drug Policy; 2015 Oct; 26(10):984-91. PubMed ID: 26256938
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The common sense model applied to hepatitis C: a qualitative analysis of the impact of disease comparison and witnessed death on hepatitis C illness perception.
    Safo SA; Batchelder A; Peyser D; Litwin AH
    Harm Reduct J; 2015 Jun; 12():20. PubMed ID: 26092261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of treatment willingness on specialist assessment and treatment uptake for hepatitis C virus infection among people who use drugs: the ETHOS study.
    Alavi M; Micallef M; Fortier E; Dunlop AJ; Balcomb AC; Day CA; Treloar C; Bath N; Haber PS; Dore GJ; Grebely J;
    J Viral Hepat; 2015 Nov; 22(11):914-25. PubMed ID: 25996567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are Interferon-Free Direct-Acting Antivirals for the Treatment of HCV Enough to Control the Epidemic among People Who Inject Drugs?
    Lima VD; Rozada I; Grebely J; Hull M; Lourenco L; Nosyk B; Krajden M; Yoshida E; Wood E; Montaner JS
    PLoS One; 2015; 10(12):e0143836. PubMed ID: 26633652
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Changes in risk behaviours during and following treatment for hepatitis C virus infection among people who inject drugs: The ACTIVATE study.
    Midgard H; Hajarizadeh B; Cunningham EB; Conway B; Backmund M; Bruggmann P; Bruneau J; Bourgeois S; Dunlop A; Foster GR; Hellard M; Robaeys G; Thurnheer MC; Weltman M; Amin J; Marks PS; Quiene S; Dore GJ; Dalgard O; Grebely J;
    Int J Drug Policy; 2017 Sep; 47():230-238. PubMed ID: 28633998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.